What is Vertex's most significant development program?

Vertex's most significant development program is for telaprevir (VX-950), an oral hepatitis C protease inhibitor. The company is conducting late-stage (Phase 2b) clinical trials and plans to initiate Phase 3 trials in the second half of 2007, with a strategy to retain commercial rights in North America.

How is Vertex funding its extensive research and development activities?

Vertex is funding its R&D through a combination of existing cash reserves, revenue from royalties on its HIV drug (Lexiva/Telzir), and significant upfront payments and development funding from its collaborative partners, such as the recent deal with Janssen for telaprevir. The company also completed a public offering of its common stock in 2006 to bolster its financial resources.

What are the key risks facing Vertex in the near future?

Key risks include the successful completion and regulatory approval of telaprevir, as its development consumes a significant portion of Vertex's resources. Other risks include the inherent uncertainties of drug development (clinical trial failures, regulatory delays), competition from other companies developing similar therapies, and the need to build commercialization capabilities for telaprevir in North America, an area where Vertex has limited experience.

What is the status of Vertex's other drug candidates?

Vertex is advancing other drug candidates including VX-702 (for rheumatoid arthritis, in Phase 2 trials), VX-770 (for cystic fibrosis, entering Phase 2 trials), and VX-883 (for bacterial infections, in preclinical development with plans for Phase 1 trials). Several other candidates are in development through collaborations with companies like Merck and GlaxoSmithKline.

VRTX 10-K FY2006 Annual Report — Revenue, Net Income, EPS

Summary

Vertex Pharmaceuticals, Inc. (VRTX) reported its fiscal year results for 2006, highlighting significant investment in its drug development pipeline, particularly for its lead candidate, telaprevir (VX-950), targeting Hepatitis C virus (HCV) infection. The company is advancing telaprevir through late-stage clinical trials and is building infrastructure for its potential commercialization in North America. Vertex also has other promising drug candidates in development for indications such as rheumatoid arthritis (VX-702), cystic fibrosis (VX-770), and bacterial infections (VX-883), with varying degrees of collaboration with other pharmaceutical companies. Financially, Vertex continued to experience operating losses, consistent with its strategy of investing heavily in research and development. However, the company strengthened its balance sheet by increasing its cash reserves significantly, primarily through a public offering of common stock and an upfront payment from a new collaboration with Janssen Pharmaceutica for telaprevir. While facing significant risks inherent in drug development, including regulatory hurdles and competitive pressures, Vertex's strategic focus on telaprevir and its efforts to build internal commercial capabilities position it for potential future growth.

Key Highlights

1Vertex is heavily investing in the development of telaprevir (VX-950), its lead drug candidate for Hepatitis C (HCV), with Phase 2b trials ongoing and plans for Phase 3 trials in the second half of 2007.

2The company is building its internal capabilities for clinical development, regulatory affairs, quality control, and commercial supply chain management in preparation for the potential launch of telaprevir in North America.

3Vertex has a diversified pipeline with other drug candidates in development, including VX-702 for rheumatoid arthritis, VX-770 for cystic fibrosis, and VX-883 for bacterial infections.

4The company secured significant financing in 2006, including a public offering of common stock and a substantial upfront payment from a new collaboration with Janssen for telaprevir.

5Vertex continues to rely on collaborations for the development and commercialization of certain drug candidates, such as the ongoing collaboration with GlaxoSmithKline for HIV treatments and with Merck for oncology treatments.

6The company reported a net loss for 2006, reflecting its substantial investments in research and development, but saw an increase in total revenues driven by new and existing collaborations.

7Vertex maintains a strong cash position, which it believes is sufficient to fund its operations for at least the next eighteen months, while acknowledging the need for potential future capital raises.

VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2006

Summary

Key Highlights

Frequently Asked Questions